CAC 40
7 320,78 -25,37 (-0,35 %) Euro Stoxx 50
4 411,62 -6,89 (-0,16 %) Dow Jones
36 245,50 +294,60 (+0,82 %) EUR/USD
1,0848 -0,0037 (-0,34 %) Gold future
2 077,40 -12,30 (-0,59 %) Bitcoin EUR
38 530,60 +1 903,68 (+5,20 %)
MRK Apr 2024 90.000 call
| Clôture précédente | 14,80 |
| Ouverture | 14,80 |
| Offre | 0,00 |
| Vente | 0,00 |
| Prix d’exercice | 90,00 |
| Date d’expiration | 2024-04-19 |
| Var. jour | 14,80 - 14,80 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 60 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
